Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020110089 - UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES

Publication Number WO/2020/110089
Publication Date 04.06.2020
International Application No. PCT/IB2019/060337
International Filing Date 29.11.2019
IPC
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 47/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 9/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases
CPC
A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/37
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
37Coumarins, e.g. psoralen
A61K 47/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 9/0014
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0014Skin, i.e. galenical aspects of topical compositions
A61K 9/7023
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases ; ; Films; Fibres of the matrix type containing drug;
7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Applicants
  • WARSZAWSKI UNIWERSYTET MEDYCZNY [PL]/[PL]
Inventors
  • PIWOWARSKI, Jakub
  • GRANICA, Sebastian
  • SACHARCZUK, Mariusz
  • NARUSZEWICZ, Marek
Agents
  • ZEBROWSKA-KUCHARZYK, Agnieszka
Priority Data
P.42794429.11.2018PL
Publication Language English (EN)
Filing Language Polish (PL)
Designated States
Title
(EN) UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES
(FR) UROLITHINE A ET COMPOSITION LA CONTENANT POUR UTILISATION EXTERNE DANS DES INFLAMMATIONS DE DIVERSES ÉTIOLOGIES
Abstract
(EN)
The invention relates to the compound urolithin A and its compositions for topical use in inflammatory skin conditions of various etiologies. Anti-inflammatory activity has been demonstrated in vivo in a model of inflammation of the ear caused by infiltration with dinitrochlorobenzene in rats. Topical application of an ointment containing 0.2 and 1.0% urolithin A resulted in a decrease in ear edema and scratching frequency, which was associated with a decrease in the number of immune cells responsible for the progression of inflammation. The results obtained indicate the possibility of using a composition containing urolithin A in local therapy of skin inflammations, in treatment of which hydrocortisone or other steroids are currently used.
(FR)
L'invention concerne le composé constitué par l'urolithine A et les compositions à usage topique à base de celui-ci utilisées dans des affections inflammatoires cutanées de diverses étiologies. Une activité anti-inflammatoire a été démontrée in vivo dans un modèle d'inflammation de l'oreille provoquée par une infiltration de dinitrochlorobenzène chez des rats. L'application topique d'une pommade contenant 0,2 à 1,0 % d'urolithine A conduit à une diminution de l’œdème de l'oreille et de la fréquence de grattage, en association avec une diminution du nombre de cellules immunitaires responsables de la progression de l'inflammation. Les résultats obtenus indiquent la possibilité d'utiliser une composition contenant de l'urolithine A en traitement local d'une inflammation cutanée, dans le traitement de laquelle l'hydrocortisone ou d'autres stéroïdes sont actuellement utilisés.
Latest bibliographic data on file with the International Bureau